Pharmacological abrogation of S-phase checkpoint enhances the anti-tumor activity of gemcitabine in vivo.
about
Centrosome-associated regulators of the G(2)/M checkpoint as targets for cancer therapySynthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancerTrial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapyDNA Damage Signalling and Repair Inhibitors: The Long-Sought-After Achilles' Heel of CancerTargeting the Checkpoint to Kill Cancer CellsChemotherapeutic compounds targeting the DNA double-strand break repair pathways: the good, the bad, and the promisingCellular inhibition of checkpoint kinase 2 (Chk2) and potentiation of camptothecins and radiation by the novel Chk2 inhibitor PV1019 [7-nitro-1H-indole-2-carboxylic acid {4-[1-(guanidinohydrazone)-ethyl]-phenyl}-amide].Context-Dependent Cell Cycle Checkpoint Abrogation by a Novel Kinase InhibitorStructure-Guided Evolution of Potent and Selective CHK1 Inhibitors through Scaffold MorphingPerspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancerCell cycle checkpoint in cancer: a therapeutically targetable double-edged swordThe cancer therapeutic potential of Chk1 inhibitors: how mechanistic studies impact on clinical trial designGemcitabine induces poly (ADP-ribose) polymerase-1 (PARP-1) degradation through autophagy in pancreatic cancerCentromere fragmentation is a common mitotic defect of S and G2 checkpoint override.Chk1 inhibition in p53-deficient cell lines drives rapid chromosome fragmentation followed by caspase-independent cell deathPhase I dose-escalation study of milciclib in combination with gemcitabine in patients with refractory solid tumors.Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair.Cytokinetically quiescent (G0/G1) human multiple myeloma cells are susceptible to simultaneous inhibition of Chk1 and MEK1/2.A novel Chk inhibitor, XL-844, increases human cancer cell radiosensitivity through promotion of mitotic catastrophe.New insights into checkpoint kinase 1 in the DNA damage response signaling network.Single-nucleotide polymorphisms of DNA damage response genes are associated with overall survival in patients with pancreatic cancerMET Inhibition Results in DNA Breaks and Synergistically Sensitizes Tumor Cells to DNA-Damaging Agents Potentially by Breaching a Damage-Induced Checkpoint ArrestAssessment of chk1 phosphorylation as a pharmacodynamic biomarker of chk1 inhibition.MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenograftsTriple-negative breast cancer: are we making headway at least?Identification of DNA repair pathways that affect the survival of ovarian cancer cells treated with a poly(ADP-ribose) polymerase inhibitor in a novel drug combination.CCT244747 is a novel potent and selective CHK1 inhibitor with oral efficacy alone and in combination with genotoxic anticancer drugs.New combination therapies with cell-cycle agentsMolecular targets and mechanisms of radiosensitization using DNA damage response pathways.Dissociation of gemcitabine chemosensitization by CHK1 inhibition from cell cycle checkpoint abrogation and aberrant mitotic entry.CDC25 phosphatases in cancer cells: key players? Good targets?G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancerCCT241533 is a potent and selective inhibitor of CHK2 that potentiates the cytotoxicity of PARP inhibitors.Significant associations of mismatch repair gene polymorphisms with clinical outcome of pancreatic cancer.Improving gemcitabine-mediated radiosensitization using molecularly targeted therapy: a reviewCheckpoint kinase inhibitors: a review of the patent literature.Inhibition of homologous recombination with vorinostat synergistically enhances ganciclovir cytotoxicity.Harnessing the complexity of DNA-damage response pathways to improve cancer treatment outcomes.Mitosis-targeted anti-cancer therapies: where they stand.Therapeutic potential of investigational CHK-1 inhibitors for the treatment of solid tumors.
P2860
Q21245716-7F5470AB-7230-48A1-885F-E2872478F58AQ24657439-143E6C1C-EB4D-48BA-93C8-0B4C1F62ED3CQ26745686-440DAC16-898D-4527-89D8-C03E414E8E75Q26776513-2A4F4261-779C-4032-8557-E286A5C76D29Q26795781-F467A463-F518-49F2-A323-495C3498D3DDQ26863501-CADF6DFE-DD4D-4F7F-A27A-19DEE56B3C6DQ27657380-5A40641A-2D32-4750-9199-A510DBED2F89Q27665373-944A9592-3463-4EB4-B61C-04F6100CEB08Q27675773-8D89A325-0CB1-4B93-8BE3-E9C40806A8F9Q28066320-E5C31C98-CE2D-489D-9CD1-47D54521E500Q28078268-28552260-28F3-4311-B8FC-20133F5ECB20Q28289090-02421FE7-DA18-490C-8464-30EB11E37031Q28543464-F5C5F0CC-09B6-42CD-9E57-482D268880D2Q30540593-2ACD79BA-B439-45D9-8495-B19463195BE8Q30570001-F56BCDBF-8E65-4E0E-A14C-BA852AD6C288Q33441161-7B0DC39D-4DC5-45DD-9A33-A2629B4AB765Q33926817-CB7FB99F-131E-4B8D-8DFA-B12D0808DC6FQ34017354-4F97AE41-73E0-4C7E-B730-2BBEECA23032Q34089160-B5FF5223-36F9-4AC3-B4C4-DF44B1861CD3Q34129155-D33C50A1-DCE1-49E0-8483-11C8487F1CBFQ34766691-B0678752-85A3-4749-95D4-2662C30860E6Q34972637-81930848-4AB4-4707-811A-3517F7071316Q35023976-71C0E27A-CC94-44AD-AECD-3ADD8B936005Q35839058-E1E89C63-BA97-42A8-B18C-AEF279417097Q36061177-4C5C1EEF-B35C-4823-AEC0-D585A3DA17C0Q36294441-A1997C84-F9A8-4C74-B19B-2032943A66BAQ36328196-251B852F-F6BD-4E9E-8CC3-FBBC57275E8EQ36737314-717FC24B-25E7-497C-8AE0-9502B6C28A5FQ36792626-2463A029-E650-4A7A-A17E-AE25B96CE175Q36838392-250584FE-17F1-4918-8F83-9A1C1CE663C0Q36849329-D05AB317-B23E-427F-B2A3-BC1D8BFED84CQ37071564-C30DE4C3-AA50-4115-B31C-A2BF42E6C366Q37103465-8DCE34E4-CA44-4729-B4E9-4EEE6AF7C546Q37158252-F4E09036-943D-4592-A10F-5B2AE73A2397Q37230970-F32426CE-93E2-41DB-B245-695B79C0EAC7Q37481298-18B8D020-8604-4771-9CCB-8CDCA8DAB7EDQ37579567-327C37C0-C588-4BA2-BF88-AB84051D0B1CQ37785490-C7128A2D-E64C-40E2-980C-3FFB023D2CB7Q38053055-7B131E94-B304-4034-81A3-1F1E7FC68D6EQ38660811-277AF087-F73B-41D4-800F-7355F97D23A0
P2860
Pharmacological abrogation of S-phase checkpoint enhances the anti-tumor activity of gemcitabine in vivo.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Pharmacological abrogation of ...... tivity of gemcitabine in vivo.
@en
Pharmacological abrogation of ...... tivity of gemcitabine in vivo.
@nl
type
label
Pharmacological abrogation of ...... tivity of gemcitabine in vivo.
@en
Pharmacological abrogation of ...... tivity of gemcitabine in vivo.
@nl
prefLabel
Pharmacological abrogation of ...... tivity of gemcitabine in vivo.
@en
Pharmacological abrogation of ...... tivity of gemcitabine in vivo.
@nl
P2093
P356
P1433
P1476
Pharmacological abrogation of ...... tivity of gemcitabine in vivo.
@en
P2093
Albert Tai
David J Matthews
Douglas O Clary
F Michael Yakes
Jason Chen
Jill M Wagner
Larry M Karnitz
Lester Bornheim
Louis Murray
Michele Tadano
P304
P356
10.4161/CC.6.1.3699
P577
2007-01-07T00:00:00Z